Atopic Dermatitis

Dermatology is gearing up for the upcoming 18th Annual South Beach Symposium in Miami Beach, Florida, from Feb. 6 to 9, 2020.

Findings from a phase 3 clinical trial support the use of weight-based Dupixent dosing in adolescents with moderate to severe atopic dermatitis.

In the top story from last week, Deanne Mraz Robinson, MD, describes how at-home therapy, such as LED light therapy along with in-office platelet-rich plasma injections, helps to prevent further hair loss and protect the hair growth already achieved.

Combination treatment with baricitinib and topical corticosteroids was associated with a higher proportion of patients achieving clear or almost clear skin, according to data from the BREEZE-AD7 trial.

Abrocitinib, in both 100 mg and 200 mg doses, significantly improved Investigator Global Assessment and Eczema Area and Severity Index-75 scores in patients with moderate to severe atopic dermatitis compared with placebo, meeting all endpoints in the phase 3 JADE MONO-1 study, which was presented at the European Academy of Dermatology and Venereology Congress.

Bermekimab, which neutralizes interleukin-1 alpha, improved all disease measures of atopic dermatitis, including a large reduction in pruritus, according to phase 2 trial results presented at the European Academy of Dermatology and Venereology Congress by Alice Gottlieb, MD, PhD, of Icahn School of Medicine at Mount Sinai.

Interleukin-13 may be the central cytokine in the skin of patients with atopic dermatitis, and by blocking interleukin-13 with targeted therapies it is possible to block many key disease characteristics such as skin barrier deficiency, according to research presented at European Academy of Dermatology and Venereology Congress.

Researchers have identified a minimally invasive technique using tape strips to study the phenotype and specific biomarkers in children with atopic dermatitis, in a popular story at Healio Dermatology, just in time for National Eczema Awareness Month.

Dupixent does not appear to exert an overarching dampening effect on patch test results, according to research published in Journal of the American Academy of Dermatology.

Dermira announced treatment commencement in the first patient for a phase 3 study evaluating lebrikizumab in adult and adolescents with moderate to severe atopic dermatitis.